Treviso, December 1st, 2025 – SolidWorld Group S.p.A., listed on Euronext Growth Milan (ticker: S3D), is an Italian technology group, leader in the integration of advanced 3D digital solutions and artificial intelligence, for the industrial, biomedical and defense sectors, is strengthening the position of its biomedical division with Electrospider, the first Italian 3D bioprinter protected by a global patent. The platform combines scientific research with industrial capability, opening new perspectives for regenerative medicine and personalised medicine.
Electrospider is a multiscale, multimaterial 3D bioprinting platform capable of producing complex cellularized constructs and in-vitro biological tissue models, accelerating experimentation in controlled and reproducible conditions and supporting the use of bioprinting technologies in industrial and clinical settings. To date, it is a technology already adopted by research centres and clinical institutions to biofabricate 3D biological constructs able to simulate the functionality of human tissues and support the development of new therapeutic approaches.
The Group’s biomedical division operates through two complementary entities:
- Bio3DModel, a Group company specialising in anatomical 3D printing for surgical planning, which enables surgeons to prepare a procedure by studying the patient’s specific anatomy, and clinical training, producing customised models based on CT and MRI scans. The company has recently obtained ISO 13485 international certification, the reference standard for the quality of medical devices.
- Bio3DPrinting, a spin-off of the University of Pisa, has developed Electrospider, a multiscale, multimaterial 3D bioprinting ecosystem based on a multifunctional printing head capable of integrating up to five different biofabrication technologies. This means that, within a single printing session, it is possible to combine different biomaterials and obtain structures ranging from millimetric elements to nanometric components.
This design enables the generation of complex cellular constructs and highly faithful in-vitro models, useful for studying tissue behaviour under controlled conditions. This allows researchers to observe how a tissue responds to a therapy, to test drugs in preclinical phases, and to work on personalised cellular structures reflecting the characteristics of each patient.
Thanks to this ability to replicate biological complexity in the laboratory, Electrospider opens the way to new possibilities in translational research, in the study of complex diseases, and in the development of patient-specific therapeutic strategies.
In recent years, Electrospider has been adopted by leading research centres and industrial organisations, both national and international, including major hospital institutes, where the platform is used for oncology research, the generation of complex tissues and, in perspective, the development of constructs for applications in transplantation. It represents a clear example of concrete technological transfer: from university, to the laboratory, and up to advanced clinical use.
Electrospider is an open platform, designed to evolve alongside the needs of researchers and developed to integrate with the requirements of products intended for clinical and industrial use. The technology incorporates a proprietary Artificial Intelligence developed by SolidWorld Group, which optimises the construction of the digital organ model and ensures maximum precision in the biofabrication process.
Roberto Rizzo, President and CEO of SolidWorld Group, states:“Electrospider is one of the most ambitious technological ventures we have undertaken. It represents the synthesis between scientific research and industrial vision, combining Italian academic excellence with the innovative and manufacturing capacity of our Group. The bioprinter turns the potential of 3D printing into real opportunities for the medicine of the future. Today we are not presenting a result, but a journey: the construction of a technology destined to change the way we treat, study and understand the human body.”
Giovan Battista Semplici, CEO of Bio3DPrinting, adds: “Electrospider is the result of extensive research and stems from the desire to overcome the limits of traditional bioprinting, combining different techniques in a single system capable of managing a wide range of biomaterials across different scales. Every day, we work to make our technology increasingly aligned with the needs of researchers and users in clinical or industrial contexts, in terms of usability, quality and reliability.
With its biomedical division, SolidWorld Group confirms its long-term vision: to build an Italian 3D bioprinting supply chain capable of competing internationally and bringing additive technologies into the service of life.
***
SolidWorld Group S.p.A. listed on Euronext Growth Milan (ticker: S3D), is an Italian technology group leader in the integration of advanced 3D digital solutions and artificial intelligence, serving strategic and next-generation industrial sectors. Founded in the early 2000s by engineer Roberto Rizzo, the Group drives the transformation of manufacturing companies toward “Factory 5.0” through proprietary software and hardware technologies that make production processes faster, more sustainable, and more efficient. Comprising 10 companies, 14 locations 3 tech hubs, and over 178 employees SolidWorld serves more than 10,000 clients. Key innovations include Electrospider, a 3D bioprinter capable of replicating human tissues and organs. As of December 31, 2024, the Group recorded a Value of Production equal to Eur 66,2 million and an EBITDA of Eur 6.5 million. www.solidworldgroup.it
CONTACTS
Investor Relations Manager
Elisabetta Cammarata
investor@solidworld.it
IR & Media Relations Advisor
Image Building Società Benefit
solidworld@imagebuilding.it – Tel. +39 02 89011300
Euronext Growth Advisor & Specialist
Integrae SIM | info@integraesim.it | T: 02 80 50 61 60 | Piazza Castello, 24 Milano
